JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study
Masroor, Mirza; Amit, Jain; Javid, Jamsheed; Mir, Rashid; Prasant, Y; Imtiyaz, A; Mariyam, Z; Mohan, Anant; Ray, PC; Saxena, Alpana;
  PDF(new window)
 Abstract
Background: The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. Materials and Methods: This casecontrol study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves. Results: It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p
 Keywords
EGF gene (+61A/G) polymorphism;AS-PCR;NSCLC (ADC) patients;
 Language
English
 Cited by
1.
Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study, Tumor Biology, 2016, 37, 8, 10479  crossref(new windwow)
 References
1.
Aaronson SA (1991). Growth factors and cancer. Science 1991. 254, 1146-53. crossref(new window)

2.
Alberg AJ, Brock MV, Samet JM (2005). Epidemiology of lung cancer: Looking to the future. J Clin Oncol, 23, 3175-85. crossref(new window)

3.
Araujo A, Ribeiro R, Azevedo I, et al (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist, 12, 201-10. crossref(new window)

4.
Carpenter G, Cohen S (1990). Epidermal growth factor. J Biol Chem, 265, 7709-12.

5.
Ciardiello F, Tortoa G (2008). EGFR antagonist in cancer treatment. N Engl J Med, 358, 1160-74. crossref(new window)

6.
Ciardiello F, Tortoa G (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958-70.

7.
Costa BM, Ferreira P, Costa S, et al (2007). Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res, 13, 2621-6. crossref(new window)

8.
Gan HK, Burgess AW, Clayton AHA, et al (2012). Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res, 72, 2924-30. crossref(new window)

9.
Goto Y, Ando T, Goto H, et al (2005). No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev, 14, 2454-6. crossref(new window)

10.
Goustin AS, Leof AB, Shipley GD (1986). Growth factors and cancer. Cancer Res, 46, 1015-1029.

11.
Harris R, Chung E, Coffey RJ, et al (2003). EGF receptor ligands. Exp Cell Res, 284, 2-13. crossref(new window)

12.
Hu-Lieskovan S, Vallbohmer D, Zhang W, et al (2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res, 17, 5161-9. crossref(new window)

13.
Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54. crossref(new window)

14.
Ichiro Okamoto, Florian Roka, Julia Krogler, et al (2006). The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. Journal of Investigative Dermatology, 126, 2242-6. crossref(new window)

15.
Kang H, Choi JE, Lee WK, et al (2007). +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology, 12, 902-5. crossref(new window)

16.
Kenneth K. Tanabe, Antoinette Lemoine, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis, JAMA, 299, 53-60.

17.
Laurence DJ, Gusterson BA (1990). The epidermal growth factor: A review of structural and functional relationships in the normal organism and in cancer cells. Tumor Biol, 11, 229-61. crossref(new window)

18.
Lim Y, Kim JW, Song JY, et al (2005). Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett, 374, 157-60. crossref(new window)

19.
Li T, Ke-Wei Ren, and Peng-Fei Liu (2012). Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol.

20.
Moulder SL, Yakes FM, Muthuswamy SK, et al (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ neu (erbB2) overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 61, 8887-95.

21.
Naruke T, Tsuchiya R, Kondo H, et al (1997). Implications of staging in lung cancer. Chest, 112, 242-8. crossref(new window)

22.
Salomon DS, Brandt R, Ciardello F, et al (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19, 183-232. crossref(new window)

23.
Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401. crossref(new window)

24.
Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92. crossref(new window)

25.
Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8. crossref(new window)

26.
Teixeira A, et al (2008). Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res, 14, 3367-71. crossref(new window)

27.
Vauleon E, Auger N, Benouaich-Amiel A, JY, Thillet J, Sanson M: The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172, 33-37.

28.
Wu G, Hasenberg T, Magdeburg R, et al (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg, 33, 124-9. crossref(new window)

29.
Ying Piao, Liu Z, Ding Z, et al (2013). EGF +61A>G polymorphism and gastrointestinal cancer risk: a HuGE review and meta-analysis. Gene, 519, 26-33. crossref(new window)

30.
Zhang YM, Cao C, Liang K (2010). Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a metaanalysis. Cancer Epidemiol, 34, 150-6. crossref(new window)